Cellid, Co., Ltd. (KOSDAQ:299660)
South Korea · Delayed Price · Currency is KRW 4,195.00
+175.00 (4.35%)
Sep 19, 2025, 3:30 PM KST
Cellid, Revenue
In the year 2024, Cellid, had annual revenue of 4.17B KRW. Cellid, had revenue of 1.88B in the quarter ending December 31, 2024.
Revenue
4.17B
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
123.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.17B | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 480.00M | -429.09M | -47.20% |
| Dec 31, 2021 | 909.09M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |